Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Peregrine Pharmaceuticals (NASDAQ:PPHM) is scheduled to be releasing its Q314 earnings data on Friday, March 7th. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was 47.64% in last session and finished the day at $2.82. Traded volume was 36.76million shares in the last session and the average volume of the stock remained 3.12million shares. The beta of the stock remained 1.40. Peregrine Pharmaceuticals (NASDAQ:PPHM) insider ownership is 16%.

Bristol-Myers Squibb Co (NYSE:BMY) said its treatment showed promising results in a Phase IIb study that compared its investigational compound–known as BMS-663068–with Reyataz boosted with ritonavir. Bristol-Myers Squibb Co (NYSE:BMY) rose 0.34 percent to $56.61 yesterday on volume of 8.94million shares. The intra-day range of the Bristol-Myers Squibb Co (NYSE:BMY) stock was $55.52 to $57.06. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $93.42billion.

Abbott Laboratories (NYSE:ABT) was upgraded by equities researchers at Thomson Reuters/Verus from a “hold” rating to a “buy” rating in a research report issued on Monday. Abbott Laboratories (NYSE:ABT)’s stock on Mar 05, 2014 reported a decrease of -0.82% to the closing price of $39.79. Its fifty two weeks range is $32.70 -$40.49. The total market capitalization recorded $61.40billion. The overall volume in the last trading session was 8.29million shares. In its share capital, Abbott Laboratories (NYSE:ABT) has 1.55billion outstanding shares.

Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Eli Lilly and Company’s ( LLY ) Evista (60 mg). On Wednesday, shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) advanced 0.79% to close the day at $49.80. Company return on investment (ROI) is 4.90% and its monthly performance is recorded as 13.98%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) quarterly revenue growth is 23.48%.